Drugs / Taldefgrobep Alfa
Taldefgrobep Alfa
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02145234 | Jun 2014 → Feb 2016 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07281495 | Nov 2025 → Sep 2026 overdue | obesity disorder | Biohaven Therapeutics Ltd. | Active not recruiting | No outcome recorded |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT03039686 | Jul 2017 → Apr 2020 | Duchenne muscular dystrophy | Hoffmann-La Roche | Completed | Missed primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT05337553 | Jul 2022 → Sep 2024 overdue | spinal muscular atrophy | Biohaven Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT03100630 Comparator | May → Oct 2017 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/2 | NCT02515669 Comparator | Dec 2015 → Feb 2018 | Duchenne muscular dystrophy | Hoffmann-La Roche | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | taldefgrobep alfa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05337553 ↗ |
| Known as | BMS-986089 | “Study of an Investigational Drug, RO7239361 (BMS-986089), in Ambulatory Boys With DMD” NCT02515669 ↗ |
| Known as | RO7239361 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02515669 ↗ |
| Known as | Talditercept alfa | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297914 ↗ |
| Action | Inhibit | “directly blocks myostatin activity” NCT05337553 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL4297914 ↗ |
| Route | Subcutaneous | “BMS-986089 in a single subcutaneous administration” NCT02145234 ↗ |